➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Harvard Business School
Baxter
Medtronic
Moodys

Last Updated: June 1, 2020

DrugPatentWatch Database Preview

Patent: 5,886,145

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,886,145
Title: Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
Abstract:New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
Inventor(s): Guilloux; Yannick (Nantes, Cedex, FR), Jotereau; Francine (Nantes, Cedex, FR), Boon-Falleur; Thierry (Brussels, BE), Lucas; Sophie (Brussels, BE), Brichard; Vincent (Brussels, BE)
Assignee: INSERM (Institute National de la Sante et de la Rechereche Medicale) (Paris, FR)
Application Number:08/915,972
Patent Claims:see list of patent claims

Details for Patent 5,886,145

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial INSERM (Institute National de la Sante et de la Rechereche Medicale) (Paris, FR) 2015-06-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial INSERM (Institute National de la Sante et de la Rechereche Medicale) (Paris, FR) 2015-06-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial INSERM (Institute National de la Sante et de la Rechereche Medicale) (Paris, FR) 2015-06-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Baxter
McKinsey
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.